Text · Report parliamentary committee draft
On the proposal for a regulation of the European Parliament and of the Council on monitoring and controlling drug precursors and repealing Regulations (EC) No 273/2004 and (EC) No 111/2005
Document CJ75-PR-788848 · COM(2025)0747 – C100326/2025 – 2025/0384(COD)
- Kind
- Report parliamentary committee draft CJ75-PR-788848
- Date
- 20 May 2026
- Committee
- Committee on International Trade Committee on Civil Liberties, Justice and Home Affairs
- Rapporteur
- Nicolas Bay, Bartłomiej Sienkiewicz
- Dossier
- 2025-0384
More facts (3)
- Formats
- Official page PDF Word
- Subject matter
- MARI, SANT
- Reference
- COM(2025)0747 – C100326/2025 – 2025/0384(COD)
Text
The text as parsed from the official Word file. Every paragraph has a link (¶) and can be saved to a project as a passage.
Jump to an amendment (35)
- Amendment 1
- Amendment 2
- Amendment 3
- Amendment 4
- Amendment 5
- Amendment 6
- Amendment 7
- Amendment 8
- Amendment 9
- Amendment 10
- Amendment 11
- Amendment 12
- Amendment 13
- Amendment 14
- Amendment 15
- Amendment 16
- Amendment 17
- Amendment 18
- Amendment 19
- Amendment 20
- Amendment 21
- Amendment 22
- Amendment 23
- Amendment 24
- Amendment 25
- Amendment 26
- Amendment 27
- Amendment 28
- Amendment 29
- Amendment 30
- Amendment 31
- Amendment 32
- Amendment 33
- Amendment 34
- Amendment 35
Draft european parliament legislative resolution
–having regard to Article 294(2) and Articles 33, 114 and 207 of the Treaty on the Functioning of the European Union, pursuant to which the Commission submitted the proposal to Parliament (C100326/2025),
–having regard to the joint deliberations of the Committee on International Trade and the Committee on Civil Liberties, Justice and Home Affairs under Rule 59 of the Rules of Procedure,
–having regard to the report of the Committee on International Trade and the Committee on Civil Liberties, Justice and Home Affairs (A100000/2026),
2.Calls on the Commission to refer the matter to Parliament again if it replaces, substantially amends or intends to substantially amend its proposal;
3.Instructs its President to forward its position to the Council, the Commission and the national parliaments.
| Text proposed by the Commission | Amendment |
|---|---|
| (5a) The administrative simplification and digitalisation provided for in this Regulation should not result in a disproportionate reduction in the ability of the competent authorities to monitor intra-Union movements of drug precursors which present a high risk of diversion towards the illicit manufacture of drugs. It is therefore appropriate to adopt proportionate traceability and risk-analysis tools, while respecting the proper functioning of the internal market. |
| Text proposed by the Commission | Amendment |
|---|---|
| (6a) The illicit diversion and trafficking of drug precursors have evolved significantly in recent years, notably through the rapid emergence of new synthetic drugs, non-scheduled drug precursors lacking legally binding obligations, sophisticated methods of chemical concealment and transformation and the increased use of online platforms and cross-border supply chains. Those developments have substantially changed the nature, scale and complexity of the drug phenomenon within the Union and require a coherent, modern and adaptable legal framework. In that context, it is key for Council Framework Decision 2004/757/JHA1 to be reassessed and, where appropriate, revised in order to ensure that the Union legal framework remains effective, proportionate and fit for purpose in addressing current and emerging challenges related to illicit drug manufacture, illicit drug trafficking and the illicit diversion of drug precursors. Enhanced alignment between this Regulation and the criminal law provisions of the Member States, as coordinated within the Union framework, would strengthen the protection of public health and security across the Union.) | |
| 1 Council Framework Decision 2004/757/JHA of 25 October 2004 laying down minimum provisions on the constituent elements of criminal acts and penalties in the field of illicit drug trafficking (OJ L 335 11.11.2004, p. 8, ELI: http://data.europa.eu/eli/dec_framw/2004/757/oj |
| Text proposed by the Commission | Amendment |
|---|---|
| (18a) Effective prevention of the diversion of drug precursors and the timely detection of emerging trafficking methods require a strong analytical, operational and scientific contribution at Union level. In accordance with its mandate, the European Union Drugs Agency (‘the Agency’) is best placed to support the implementation of this Regulation by providing risk assessments, strategic and operational analysis, early warning and trend monitoring, technical and scientific expertise, training activities, and support for information exchange and cooperation among competent national authorities and with relevant Union bodies and international partners. In order to ensure the effective and sustainable fulfilment of those tasks, the Agency should be provided with adequate and predictable financial and human resources, commensurate with the responsibilities entrusted to it under this Regulation and the evolving challenges posed by the illicit diversion and trafficking of drug precursors. The Commission and the Member States should therefore ensure that the Agency is able to contribute effectively to the objectives of this Regulation. |
| Text proposed by the Commission | Amendment |
|---|---|
| (26a) For the purposes of this Regulation, in relation to drug precursors and transactions involving drug precursors, “reasonable grounds” should be understood as referring to objective, factual and verifiable elements which, assessed in light of the circumstances of the individual case, would lead a diligent operator or competent authority to suspect that a drug precursor may be intended for the illicit manufacture of drugs. Such grounds can be derived, inter alia, from the nature, quantity or combination of substances ordered, unusual transaction patterns, inconsistencies in the information provided by the customer, atypical methods of payment, transport or delivery, the refusal to provide information required under this Regulation, or information communicated by competent authorities, the Agency or relevant Union or international bodies. The assessment of reasonable grounds should be carried out on a case-by-case basis and in a proportionate manner, taking into account the legitimate commercial and industrial uses of the substances concerned. |
| Text proposed by the Commission | Amendment |
|---|---|
| (26b) In order to ensure a consistent, effective and proportionate application of this Regulation across the Union, the Commission should, in close cooperation with the Member States and relevant Union agencies and bodies, develop and publish comprehensive guidelines supporting the implementation and enforcement of this Regulation. Those guidelines should aim to facilitate the highest possible degree of harmonisation in the interpretation and practical application of the obligations laid down in this Regulation, while taking into account national operational specificities and evolving criminal methodologies. In particular, the guidelines should include, where appropriate, detailed and regularly updated practical examples and indicators relating to: the assessment of “reasonable grounds” for suspicion under this Regulation; criteria and indicative thresholds for identifying significant seizures and suspicious transactions; examples of legitimate and licit purposes for the placing on the market, possession, import, export or use of scheduled substances and mixtures containing such substances; and examples of conduct that can constitute a breach or a circumvention of this Regulation. The guidelines should also provide operational recommendations on risk assessment, information exchange, cooperation between competent authorities and economic operators, and best practices for monitoring and enforcement of this Regulation. The Commission should ensure that the guidelines are periodically reviewed and updated in light of technological developments, emerging trafficking patterns, jurisprudence and operational experience gained by Member States. |
| Text proposed by the Commission | Amendment |
|---|---|
| (28a) Given the rapidly evolving nature of illicit drug manufacture and the increasing use of new non-scheduled substances and designer precursors by criminal networks, there can be a delay between the identification of an emerging precursor threat and the entry into force of Union measures applicable to that substance. In order to avoid regulatory gaps capable of creating serious risks to public security and public health, Member States should be able, under specific conditions and on a temporary basis, to adopt proportionate national safeguard measures pending action at Union level. Coordination with the Commission and the Agency is essential to ensuring consistency, information exchange and the proper functioning of the internal market. |
| Text proposed by the Commission | Amendment |
|---|---|
| (11) ‘making available on the market' means any supply of a drug precursor for distribution, consumption or use on the Union market in the course of a commercial activity, whether in return for payment or free of charge; | (11) ‘making available on the market' means any supply of a drug precursor for distribution, consumption or use on the Union market in the course of a commercial activity, whether in return for payment or free of charge, including via digital or other remote channels; |
| Text proposed by the Commission | Amendment |
|---|---|
| (24) ‘provider of an online marketplace’ means a provider of an online platform within the meaning of Article 3, point (i), of Regulation (EU) 2022/206528 that allows consumers or operators to conclude distance contracts with traders for the sale of scheduled drug precursors; | (24) ‘provider of an online marketplace’ means a provider of an online platform within the meaning of Article 3, point (i), of Regulation (EU) 2022/206528 that allows consumers or operators to conclude distance contracts with traders for the sale of scheduled drug precursors or non-scheduled drug precursors; |
| 28 (31)Regulation (EU) 2022/2065 of the European Parliament and of the Council of 19 October 2022 on a Single Market For Digital Services and amending Directive 2000/31/EC (Digital Services Act) (OJ L 277, 27.10.2022, p. 1, ELI: http://data.europa.eu/eli/reg/2022/2065/oj). | 28 (31)Regulation (EU) 2022/2065 of the European Parliament and of the Council of 19 October 2022 on a Single Market For Digital Services and amending Directive 2000/31/EC (Digital Services Act) (OJ L 277, 27.10.2022, p. 1, ELI: http://data.europa.eu/eli/reg/2022/2065/oj). |
| Text proposed by the Commission | Amendment |
|---|---|
| (26) ‘operator’ means any natural or legal person making available on the market, possessing or using drug precursors or any external trader of such precursors; | (26) ‘operator’ means any natural or legal person or association making available on the market, possessing or using drug precursors, whether scheduled drug precursors or non-scheduled drug precursors, or any external trader of scheduled drug precursors or non-scheduled drug precursors; |
| Text proposed by the Commission | Amendment |
|---|---|
| (34) ‘suspicious transaction’ means any transaction concerning drug precursors for which there are reasonable grounds for suspecting that the drug precursors concerned are intended for the illicit manufacture of drugs; | (34) ‘suspicious transaction’ means any transaction concerning drug precursors for which there are reasonable grounds for suspecting that the drug precursors concerned are intended for the illicit manufacture of drugs, including transactions involving non-scheduled drug precursors; |
| Text proposed by the Commission | Amendment |
|---|---|
| (b) pharmacies and dispensaries of veterinary medicinal products possessing or using Category 1 or Category 2 drug precursors, within the scope of their regular activities. | (b) pharmacies and dispensaries of veterinary medicinal products possessing or using Category 1 or Category 2 drug precursors, within the scope of their regular activities, unless there are reasonable grounds to suspect diversion or use in the illicit manufacture of drugs; |
| Text proposed by the Commission | Amendment |
|---|---|
| (a) making available on the market, possession or use of medicinal products or veterinary medicinal products; | (a) making available on the market, possession or use of medicinal products or veterinary medicinal products, unless there are reasonable grounds to suspect diversion or use in the illicit manufacture of drugs; |
| Text proposed by the Commission | Amendment |
|---|---|
| (b) import, export or intermediary activities with medicinal products or veterinary medicinal products except those listed in Part II of Annex II. | (b) import, export or intermediary activities with medicinal products or veterinary medicinal products except those listed in Part II of Annex II, without prejudice to the application of control measures where there are reasonable grounds to suspect diversion or use in the illicit manufacture of drugs; |
| Text proposed by the Commission | Amendment |
|---|---|
| 1. Operators shall provide accurate, complete and up-to-date information to the competent authority or customs authorities of the Member State concerned when fulfilling their obligations under this Regulation. | 1. Operators shall provide accurate, complete and up-to-date information to the competent authority or customs authorities of the Member State concerned when fulfilling their obligations under this Regulation and they shall, without undue delay, inform those authorities of any circumstances indicating a risk of diversion or use in the illicit manufacture of drugs. |
| Text proposed by the Commission | Amendment |
|---|---|
| 1. Operators shall report to the competent authorities immediately suspicious transactions, significant disappearances and thefts of scheduled drug precursors. Where providers of online marketplaces become aware of any information regarding suspicious transactions, significant disappearances, and thefts of scheduled drug precursors, they shall immediately report that information to the competent authorities. | 1. Operators shall report to the competent authorities immediately suspicious transactions, significant disappearances and thefts of scheduled drug precursors as well as of non-scheduled drug precursors, where there are reasonable grounds to suspect their use in the illicit manufacture of drugs. Where providers of online marketplaces become aware of any information regarding suspicious transactions, significant disappearances, and thefts of scheduled drug precursors or non-scheduled drug precursors, they shall immediately report that information to the competent authorities. |
| Text proposed by the Commission | Amendment |
|---|---|
| (a) the name of the substance covered by Annex I, Annex II or Annex III; | (a) the name of the substance covered by Annex I, Annex II or Annex III or, where applicable, the name of any non-scheduled substance; |
| Text proposed by the Commission | Amendment |
|---|---|
| (b) the quantity of the substance; | (b) the quantity of the substance covered by Annex I, Annex II or Annex III or, where applicable, the quantity of any non-scheduled substance; |
| Text proposed by the Commission | Amendment |
|---|---|
| (ca) the intended use of the substance covered by Annex I, Annex II or Annex III or, where applicable, the use of any non-scheduled substance, where such use is known; |
| Text proposed by the Commission | Amendment |
|---|---|
| (b) Category 1 drug precursors which are transhipped, placed under temporary storage, stored in a free zone, or leaving the customs territory of the Union by a re-export notification. | (b) Category 1 drug precursors which are transhipped, placed under temporary storage, stored in a free zone, or leaving the customs territory of the Union by a re-export notification, unless there are reasonable grounds to suspect diversion of those drug precursors or suspect their use in the illicit manufacture of drugs; |
| Text proposed by the Commission | Amendment |
|---|---|
| 8. The competent authorities may require operators to pay a fee for processing the application for a licence. Where a fee is levied, competent authorities shall adjust the level of the fee set for small and medium-sized enterprises. Such a fee shall be levied in a non-discriminatory manner and shall not exceed the cost of processing the application. | 8. The competent authorities may require operators to pay a fee for processing the application for a licence. Such fees may be waived or significantly reduced for universities, provided that the drug precursors are used exclusively for scientific or medical research and not for commercial purposes. Where a fee is levied, competent authorities shall adjust the level of the fee set for small and medium-sized enterprises. Such a fee shall be levied in a non-discriminatory manner, ensuring that such fees do not constitute a barrier to scientific innovation. A fee shall not exceed the cost of processing the application. |
| Text proposed by the Commission | Amendment |
|---|---|
| 5. The competent authority in the Member State of establishment of the external trader may order the external trader to suspend or cease the activities covered by the registration, where the registration does not comply with this Regulation; the conditions declared are no longer fulfilled; or, where there are reasonable grounds for suspecting that there is a risk of diversion of the scheduled drug precursors towards the illicit manufacture of drugs. | 5. The competent authority in the Member State of establishment of the external trader may, on the basis of reasonable grounds, order the external trader to suspend or cease the activities covered by the registration where the registration does not comply with this Regulation, where the declared conditions are no longer fulfilled, or where there are reasonable grounds to suspect a risk of diversion of scheduled drug precursors towards the illicit manufacture of drugs. |
| Text proposed by the Commission | Amendment |
|---|---|
| 5a. For Category 2 drug precursors presenting a high risk of diversion towards the illicit manufacture of drugs, external traders shall be subject to electronic notification allowing for the monitoring of intra-Union movements, to ensure an adequate level of traceability and to prevent diversion towards the illicit manufacture of drugs. |
| Text proposed by the Commission | Amendment |
|---|---|
| 2. Member States shall organise, at least once a year, awareness-raising actions for operators making available on the market, importing, exporting, performing intermediary activities, possessing or using drug precursors. | 2. Member States shall organise, at least once a year, awareness-raising actions, based on evidence and harm-reduction principles, for operators making available on the market, importing, exporting, performing intermediary activities, possessing or using drug precursors. Member States shall, where possible, carry out these awareness-raising actions in cooperation with industry associations. Where relevant, such actions may include sector-specific guidance. |
| Text proposed by the Commission | Amendment |
|---|---|
| Article 26a | |
| Guidelines | |
| 1. The Commission shall, in close cooperation with the Member States and, where appropriate, relevant Union agencies and bodies, develop and publish guidelines to support the consistent, effective and proportionate application of this Regulation. | |
| 2. The guidelines referred to in paragraph 1 shall aim to facilitate a high degree of harmonisation in the interpretation and practical application of the obligations laid down in this Regulation, while taking into account national operational specificities and evolving criminal methodologies. | |
| 3. The guidelines may include, where appropriate, practical examples, indicators and recommendations relating, in particular, to: | |
| (a) the assessment of reasonable grounds for suspicion under this Regulation; | |
| (b) criteria and indicative thresholds for identifying significant seizures and suspicious transactions; | |
| (c) examples of legitimate purposes for the placing on the market, possession, import, export or use of scheduled substances and mixtures containing such substances; | |
| (d) examples of conduct that can constitute a breach or a circumvention of this Regulation; | |
| (e) examples of penalties and other enforcement measures applicable in the event of infringements of this Regulation; | |
| (f) operational measures relating to the detention, seizure and disposal of scheduled substances and mixtures containing such substances; | |
| (g) operational measures and best practices for securing premises, facilities and storage locations involving scheduled substances and mixtures containing such substances; | |
| (h) risk assessment and risk-management measures; | |
| (i) the exchange of information and cooperation between competent authorities and economic operators; | |
| (j) best practices for monitoring, detection and enforcement activities. | |
| 4. The Commission shall periodically review and, where appropriate, update the guidelines, taking into account technological developments, emerging trafficking patterns, relevant jurisprudence and operational experience gained by the Member States. |
| Text proposed by the Commission | Amendment |
|---|---|
| 2a. The competent authorities of the Member States shall cooperate with each other and with the Commission to ensure the proper application and enforcement of this Regulation and shall transmit to each other all information necessary with a view to applying this Regulation uniformly. |
| Text proposed by the Commission | Amendment |
|---|---|
| 2b. The Commission shall facilitate the exchange of best practices between competent authorities of Member States in order to coordinate the uniform application of this Regulation. |
| Text proposed by the Commission | Amendment |
|---|---|
| 4. The customs authorities may temporarily detain non-scheduled drug precursors for which there is suspicion that they are intended to be used in the illicit manufacture of drugs in accordance with the conditions laid down in national law. | 4. The customs authorities or, where appropriate, the competent authorities of each Member State, may temporarily detain non-scheduled drug precursors for which there is suspicion that they are intended to be used in the illicit manufacture of drugs in accordance with the conditions laid down in national law. |
| Text proposed by the Commission | Amendment |
|---|---|
| 5. The period of temporary detention referred to in paragraph 4 shall not exceed 30 days. | 5. The period of temporary detention referred to in paragraph 4 shall not exceed 30 days. That period may, in duly justified exceptional circumstances, be extended for additional periods of 30 days in order to permit the completion of additional measures of control. |
| Text proposed by the Commission | Amendment |
|---|---|
| Article 30a | |
| Safeguard clause | |
| 1. Where a Member State identifies an emerging substance, including a non-scheduled drug precursor or combination of substances, that may be used for the illicit manufacture of drugs and which poses a serious or imminent threat to public security, public health or public safety, and where no delegated act adopted pursuant to this Regulation has yet entered into force in relation to that substance, the Member State may adopt temporary national measures which are necessary and proportionate to prevent the diversion, trafficking or illicit use of that substance. | |
| 2. The measures referred to in paragraph 1 may include restrictions concerning the manufacture, import, export, placing on the market, possession, distribution, transport or use of the substance concerned, as well as enhanced monitoring, reporting or registration obligations for operators. | |
| 3. The Member State referred to in paragraph 1 shall immediately notify the Commission and the Agency of the measures adopted pursuant to that paragraph, together with the reasons justifying those measures and any available scientific, technical or intelligence information supporting the assessment of the threat. | |
| 4. The Commission shall, without undue delay, assess whether the substance concerned should be made subject to measures at Union level, including through the adoption of a delegated act pursuant to this Regulation. | |
| 5. Measures adopted pursuant to paragraph 1 shall be temporary in nature and shall remain applicable only until the relevant Union measures enter into force or until the Member State determines that the threat no longer justifies their maintenance. Such measures shall comply with Union law and shall not constitute a means of arbitrary discrimination or a disguised restriction on trade within the internal market. |
| Text proposed by the Commission | Amendment |
|---|---|
| The level of fines shall be calculated in such way as to make sure that they effectively deprive those responsible of the economic benefits derived from the infringement concerned. The amount of the fines may be increased for repeated infringements. Member States may also impose other penalties including the seizure of the substance concerned or the immediate suspension of the authorisation to trade. |
| Text proposed by the Commission | Amendment |
|---|---|
| 3. The functions referred to in paragraph 2, points (a)(i), (ii), (iii), (iv) and (v), points (b), (c) and (d) shall be operational at the latest 18 months after the entry into force of the implementing act referred to in paragraph 8. | 3. The functions referred to in paragraph 2, points (a)(i), (ii), (iii), (iv) and (v), points (b), (c) and (d) shall be operational at the latest 12 months after the entry into force of the implementing act referred to in paragraph 8. |
| Text proposed by the Commission | Amendment |
|---|---|
| 4. The functions referred to in paragraph 2, point (a)(vi) shall be operational at the latest 6 years after the entry into force of the implementing act referred to in paragraph 8. | 4. The functions referred to in paragraph 2, point (a)(vi) shall be operational at the latest 2 years after the entry into force of the implementing act referred to in paragraph 8. |
| Text proposed by the Commission | Amendment |
|---|---|
| 8. By [OP please add date: 18 months after the entry into force of this Regulation], the Commission shall adopt an implementing act establishing implementing arrangements for the development and operation of the electronic system, including technical specifications and the procedures to be followed for the implementation of Articles 6, 8, 9, 13, 15, 17, 18, 19(1), 20, 21, 22, 23, 32, 33 and 34. | 8. By … [12 months from the date of entry into force of this Regulation], the Commission shall adopt an implementing act establishing implementing arrangements for the development and operation of the electronic system, including technical specifications and the procedures to be followed for the implementation of Articles 6, 8, 9, 13, 15, 17, 18, 19(1), 20, 21, 22, 23, 32, 33 and 34. |
| Text proposed by the Commission | Amendment |
|---|---|
| By … [five years from the date of entry into force of this Regulation] the Commission shall submit to the European Parliament and to the Council an report on the application of this Regulation. Where appropriate, that report shall be accompanied by a legislative proposal to amend this Regulation. |
| Text proposed by the Commission | Amendment |
|---|---|
| By [OP please add date: 10 years from the date of application of this Regulation], the Commission shall submit to the European Parliament and to the Council a report on the application of this Regulation. The report shall contain an assessment of how this Regulation is achieving its objectives. | By [OP please add date: 10 years from the date of application of this Regulation], the Commission shall submit to the European Parliament and to the Council a report on the application of this Regulation. The report shall contain an assessment of how this Regulation is achieving its objectives, including its impact on the availability of substances for legitimate scientific research and for innovation including for research and innovation in the medical field. |
Back matter, 1
Parts that accompany the text rather than belong to it: explanatory statement, annexes, opinions appended by other committees. Collapsed.
Explanatory statement 9 blocks
The Commission proposal for a Regulation on drug precursors represents an important step towards simplifying and modernising the Union framework governing substances that may be diverted for the illicit manufacture of drugs. The consolidation of the previous legislative framework into a single Regulation, together with the introduction of an electronic system for registrations, licences and notifications, are positive developments that should improve efficiency and legal certainty.
However, the evolving nature of organised crime, the growing use of drug precursors, including non-scheduled substances, the expansion of digital marketplaces and the differing enforcement practices among Member States require additional safeguards and targeted improvements.
The amendments introduced in the draft report therefore pursue four main objectives: strengthening harmonisation across the Union, improving the effectiveness of enforcement, addressing emerging criminal methods, and ensuring a balanced approach that does not create disproportionate burdens for legitimate operators.
The report seeks to prevent forum shopping and reduce divergences between Member States by introducing Commission guidelines on sanctions, suspicious transactions, detention conditions, significant quantities and other practical aspects of implementation. Greater harmonisation is necessary to ensure legal certainty and avoid the exploitation of weaker enforcement systems.
The report strengthens the preventive and operational capacity of competent authorities. This includes the introduction of a safeguard clause allowing for rapid action where new diversion risks emerge before a delegated act is adopted at Union level, as well as the possibility to extend the detention period beyond 30 days where there are reasonable grounds to suspect diversion for illicit drug manufacture.
The new realities linked to digitalisation and evolving criminal practices are also addressed. The definition of “making available on the market” is expanded to include digital marketplaces, reflecting the increasing use of online platforms in precursor trafficking. At the same time, the report seeks to strike a better balance between scheduled and non-scheduled substances to prevent criminal groups from shifting their activities towards substances that are less regulated. The report aims to improve the practical functioning of the Regulation by accelerating the implementation of the electronic system through shorter deadlines for implementing acts. While pharmacies and veterinaries remain outside of the scope of the Regulation, the report proposes to limit the possibility of their misuse for illicit drug production.
The report introduces amendments aimed at strengthening the traceability of the most sensitive category 2 drug precursors within the European Union and ensuring that the transition to more digitalized procedures does not create gaps in the monitoring and control capabilities of the competent authorities.
Finally, the report introduces a possibility to lift licence fees for universities in order to support legitimate scientific and research activities without weakening control mechanism.
Connections
The dossier, the decisions on this text and its other versions.
No connections found for this item.
Sources & citation
Where the facts on this page come from, and how to cite it.
- Data source
- Licensed CC BY 4.0.
- Retrieved
- 25 September 2026
Cite as
European Parliament (2026). “DRAFT REPORT on the proposal for a regulation of the European Parliament and of the Council on monitoring and controlling drug precursors and repealing Regulations (EC) No 273/2004 and (EC) No 111/2005”. Text, 20 May 2026. docId CJ75-PR-788848. EU Parl Watch Research. https://news.eu-parl.st-solutions.dev/texts/CJ75-PR-788848 (retrieved 25 September 2026). Data: EP Open Data API: document record, https://data.europarl.europa.eu/api/v2/documents/CJ75-PR-788848 (CC BY 4.0).
BibTeX
@misc{epw-text-cj75-pr-788848,
author = {{European Parliament}},
title = {{DRAFT REPORT on the proposal for a regulation of the European Parliament and of the Council on monitoring and controlling drug precursors and repealing Regulations (EC) No 273/2004 and (EC) No 111/2005}},
year = {2026},
date = {2026-05-20},
howpublished = {\url{https://news.eu-parl.st-solutions.dev/texts/CJ75-PR-788848}},
url = {https://news.eu-parl.st-solutions.dev/texts/CJ75-PR-788848},
urldate = {2026-09-25},
publisher = {EU Parl Watch Research},
note = {Text. docId CJ75-PR-788848. Data: EP Open Data API: document record (CC BY 4.0)}
}